New treatments for schizophreniaInpharma Weekly -doi:10.2165/00128413-199912100-00003NoneSpringer International PublishingInpharma Weekly
The field of schizophrenia research has come alive with many exciting new potential approaches to treatment. From the introduction of chlorpromazine to the current day, all treatments approved by the U.S. Food and Drug Administration have had, at their core, a single treatment mechanism, the bloc...
In contrast to most fields of medicine, progress to discover and develop new and improved psychiatric drugs has been slow and disappointing. The vast majority of currently prescribed drugs to treat schizophrenia, mood and anxiety disorders are arguably n
Dr. Gustavo Alva, Medical Director at ATP Clinical Research (Gus Alva MD – ATP Clinical Research) and Patrick, an adult living with schizophrenia have information about a new FDA approved treatment. Related Posts: Sickle Cell Disease: Advances in Treatments, Patient… Nicole Iny—Executive ...
As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence...
Treatments Psilocybin IVF Dental Implant Weight Loss Smoking Platelet-Rich Plasma Testosterone Saxenda Melatonin Entresto Clinical Trials by Location Depression Studies Diabetes Studies Eczema Studies Psoriasis Studies Arthritis Studies Schizophrenia Studies ...
that the finding is getting them closer to seeing what is going wrong in schizophrenia and what to target for drug treatment. And this understand of what is really going on, of what genes are involved and what they are doing is an important step for better treatments for schizophrenia. ...
Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: Implications for schizophrenia treatment Because health care payers are increasingly interested in whether new treatments offer value for money, there has been an abundance of research into the co... PJ Neumann - 《Journal...
Now, we are taking the same approach with long-acting treatments, using advanced science to improve disease outcomes for those living with schizophrenia," said Dr. Hafrun Fridriksdottir, Executive Vice President, Global R&D, at Teva. “We’re pleas...
The majority of currently available drugs are designed to target proteins coded by genes. The new finding helps to explain why schizophrenia and bipolar disorder are heritable conditions, and could provide new targets for future treatments.